Rapid design, build, test, and learn technologies for identifying and using non-viral carriers

US12031128B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-12031128-B2
Application numberUS-202217715784-A
CountryUS
Kind codeB2
Filing dateApr 7, 2022
Priority dateApr 7, 2021
Publication dateJul 9, 2024
Grant dateJul 9, 2024

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The disclosure relates to barcoded polymer nanoparticles for in vivo screening and for in vivo therapeutic delivery, and methods therefor. More particularly, the invention relates to polymer nanoparticles, such as reversible addition-fragmentation chain transfer (RAFT) polymer compositions, associated with polynucleotide barcodes, for therapeutic delivery, and for high throughput in vivo screening of drug delivery nanoparticles.

First claim

Opening claim text (preview).

What is claimed is: 1. A composition comprising: a) a non-viral delivery vehicle comprising one or more nanoparticle forming polymers, and b) a nucleic acid construct, wherein the one or more nanoparticle forming polymers are RAFT block copolymers comprising i) a first terminus comprising a first capping unit derived from a first chain transfer agent in a RAFT copolymerization process, said first chain transfer agent comprising a first reactive functional unit; ii). a first block prepared from one or more monomer units covalently attached to the first reactive functional unit, and having a molecular weight (M n ) in the range of about 1 kDa to about 200 kDa and a degree of polymerization in the range of about 10 to about 2500; iii). optionally a second block prepared from one or more monomer units covalently attached to the first block, and having a molecular weight (M n ) in the range of about 1 kDa to about 200 kDa and a degree of polymerization in the range of about 20 to about 2000; and iv) a second terminus comprising a second capping unit derived from the first or a second chain transfer agent. 2. The composition of claim 1 , wherein the non-viral delivery vehicle has one or more of an overall molecular weight (M n ) in the range of about 25 kDa to about 60 kDa, an overall degree of polymerization in the range of about 700 to about 900, a target size in the range of about of about 10 to about 60 nm, and a maximum corona-to-core ratio (CCR) of about 1.5 to about 3.5. 3. The composition of claim 1 , wherein the first block is prepared from one or more monomer units selected from the group consisting of 2-dimethylaminoethyl acrylate, 2-(diethylamino) ethyl methacrylate, 2-(diisopropylamino) ethyl methacrylate, butyl methacrylate, ethyl acrylic acid, propyl acrylic acid, (hydroxyethyl)methacrylate, and methyl methacrylate. 4. The composition of claim 1 , wherein the first block is prepared from one of 2-dimethylaminoethyl acrylate, 2-(diethylamino) ethyl methacrylate, 2-(diisopropylamino) ethyl methacrylate, butyl methacrylate, ethyl acrylic acid, propyl acrylic acid, (hydroxyethyl)methacrylate, or methyl methacrylate. 5. The composition of claim 1 , wherein the second block is prepared from one or more monomer units selected from the group consisting of 2-dimethylaminoethyl acrylate, 2-(diethylamino) ethyl methacrylate, 2-(diisopropylamino) ethyl methacrylate, butyl methacrylate, ethyl acrylic acid, propyl acrylic acid, (hydroxyethyl)methacrylate, and methyl methacrylate. 6. The composition of claim 1 , wherein the second block is a random copolymer prepared from two different monomer units independently selected from the group consisting of 2-dimethylaminoethyl acrylate, 2-(diethylamino) ethyl methacrylate, 2-(diisopropylamino) ethyl methacrylate, butyl methacrylate, ethyl acrylic acid, propyl acrylic acid, (hydroxyethyl)methacrylate, and methyl methacrylate. 7. The composition of claim 1 , wherein the second block is a random copolymer prepared from three different monomer units independently selected from the group consisting of 2-dimethylaminoethyl acrylate, 2-(diethylamino) ethyl methacrylate, 2-(diisopropylamino) ethyl methacrylate, butyl methacrylate, ethyl acrylic acid, propyl acrylic acid, (hydroxyethyl)methacrylate, and methyl methacrylate. 8. The composition of claim 1 , wherein the second block is a random copolymer prepared from 2-dimethylaminoethyl acrylate, butyl methacrylate, and propyl acrylic acid; or 2-dimethylaminoethyl acrylate and butyl methacrylate; or 2-dimethylaminoethyl acrylate, butyl methacrylate, and ethyl acrylic acid. 9. The composition of claim 1 , wherein each chain transfer agent is independently selected from the group consisting of bis(carboxymethyl)trithiocarbonate, bis(2-amino-2-oxoethyl) trithiocarbonate, bis[4-(2-hydroxyethoxycarbonyl)benzyl]trithiocarbonate, 4-cyano-4-(ethylsulfanylthiocarbonyl)sulfanylvpentanoic acid, 4-cyano-4-((phenylcarbonothioyl)thio)pentanoic acid, and 4-cyano-4-[(dodecylsulfanylthiocarbonyl)sulfanyl]pentanoic acid. 10. The composition of claim 1 , wherein the first capping unit is of the formula wherein * represents a point of covalent attachment to the first block. 11. The composition of claim 1 , wherein the second capping unit is of the formula wherein * represents a point of covalent attachment to the second block, and R is —SC 2 -C 12 alkyl or C 6 H 5 . 12. A composition of claim 1 wherein said first block is prepared from one of 2-dimethylaminoethyl acrylate, 2-(diethylamino) ethyl methacrylate, 2-(diisopropylamino) ethyl methacrylate, butyl methacrylate, ethyl acrylic acid, propyl acrylic acid, (hydroxyethyl)methacrylate, or methyl methacrylate; said second block comprises a random copolymer prepared from 2-dimethylaminoethyl acrylate, butyl methacrylate, and propyl acrylic acid; or 2-dimethylaminoethyl acrylate and butyl methacrylate; or 2-dimethylaminoethyl acrylate, butyl methacrylate, and ethyl acrylic acid; and each chain transfer agent is independently selected from the group consisting of bis(carboxymethyl)trithiocarbonate, bis(2-amino-2-oxoethyl) trithiocarbonate, bis[4(2-hydroxyethoxycarbonyl)benzyl] trithiocarbonate, 4-cyano-4-(ethylsulfanylthiocarbonyl) sulfanylvpentanoic acid, 4-cyano-4-((phenylcarbonothioyl)thio)pentanoic acid, and 4-cyano-4-[(dodecylsulfanylthiocarbonyl)sulfanyl] pentanoic acid. 13. The composition of claim 12 , wherein the first capping unit is of the formula wherein * represents a point of covalent attachment to the first block; and the second capping unit is of the formula wherein * represents a point of covalent attachment to the second block, and R is —SC 2 -C 12 alkyl or C 6 H 5 .

Assignees

Inventors

Classifications

  • using microencapsulation, e.g. using {amphiphile} liposome vesicle · CPC title

  • Hairpin oligonucleotides · CPC title

  • Branched oligonucleotides · CPC title

  • Signal amplification · CPC title

  • characterised by the detection means (C12Q1/6804 takes precedence) · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US12031128B2 cover?
The disclosure relates to barcoded polymer nanoparticles for in vivo screening and for in vivo therapeutic delivery, and methods therefor. More particularly, the invention relates to polymer nanoparticles, such as reversible addition-fragmentation chain transfer (RAFT) polymer compositions, associated with polynucleotide barcodes, for therapeutic delivery, and for high throughput in vivo screen…
Who is the assignee on this patent?
Battelle Memorial Institute
What technology area does this patent fall under?
Primary CPC classification C12N15/1065. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Jul 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).